RGLS - Regulus Therapeutics Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue721,19420,759
Cost of Revenue---
Gross Profit721,19420,759
Operating Expenses
Research Development53,19264,30556,387
Selling General and Administrative17,01118,39119,130
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-70,131-81,502-54,758
Income from Continuing Operations
Total Other Income/Expenses Net752844-956
Earnings Before Interest and Taxes-69,379-80,658-55,714
Interest Expense2,7231,18252
Income Before Tax-72,102-81,840-55,766
Income Tax Expense-197-4-18
Minority Interest---
Net Income From Continuing Ops-71,905-81,836-55,748
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-71,905-81,836-55,748
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-71,905-81,836-55,748